Secondary hematological malignancies after breast cancer chemotherapy.
According to several reports, the 10 year incidence of secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) after systemic chemotherapy is approximately 1.5%. The cumulative risk increases by 0.25--1% for the first 8 years after treatment. We have reported only 6 cases of hematological malignancies (0.3%) after breast cancer chemotherapy in our institute. We detected 2 cases of secondary AML and 1 case of MDS, 19, 52 and 12 months, respectively, after systemic chemotherapy for breast cancer. Published data on the occurrence of secondary hematological malignancies other than AML or MDS in this setting are scarce. We encountered diffuse large B-cell lymphoma, angioimmunoblastic lymphoma and mantle cell lymphoma as secondary hematological malignancies after systemic chemotherapy for breast cancer.
Park
Myung Joon
MJ
Department of Internal Medicine, Korea Institute of Radiological and Medical Science, Seoul, Korea.
Park
Yeon Hee
YH
Ahn
Heui June
HJ
Choi
Won
W
Paik
Kwang Hyun
KH
Kim
Jung Min
JM
Chang
Yoon Hwan
YH
Ryoo
Baek-Yeol
BY
Yang
Sung Hyun
SH
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects* / Q000379:methods; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D017809:Fatal Outcome; D005260:Female; D005500:Follow-Up Studies; D019337:Hematologic Neoplasms / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D008223:Lymphoma / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D016896:Treatment Outcome